dc.contributor.author | Mervin, Merehau C | |
dc.contributor.author | Lowe, Anthony | |
dc.contributor.author | Gardiner, Robert A | |
dc.contributor.author | Smith, David P | |
dc.contributor.author | Aitken, Joanne | |
dc.contributor.author | Chambers, Suzanne K | |
dc.contributor.author | Gordon, Louisa G | |
dc.date.accessioned | 2017-08-15T00:03:55Z | |
dc.date.available | 2017-08-15T00:03:55Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1743-7555 | |
dc.identifier.doi | 10.1111/ajco.12663 | |
dc.identifier.uri | http://hdl.handle.net/10072/344152 | |
dc.description.abstract | Objective: To estimate costs on the Medicare Benets Schedule (MBS) and the Pharmaceutical BenetsScheme (PBS) attributable to the diagnosis and treatment of prostate cancer.Methods: We used data from a cohort study of 1064 men with localized prostate cancer recruited between2005 and 2007 by 24 urologists across 10 sites in Queensland, Australia (ProsCan). We estimated the MBSand PBS costs attributable to prostate cancer from the date of initial appointment to 12 months after d iagnosisin 2013 Australian dollars using a comparison group without prostate cancer. We used generalized linearmodeling to identify key determinants of higher treatment-related costs.Results: From the date of initial appointment to 12 months postdiagnosis, the average MBS costs attributableto prostate cancer were $9,357 (SD $191) per patient. These MBS costs were most sensitive to having privatehealth insurance and the type of primary treatment received. The PBS costs were higher in the control groupthan in the ProsCan group ($5,641 vs $1,924).Conclusions: The costs of treating and managing prostate cancer are high and these result in a substantialnancial burden for the Australian MBS. Costs attributable to prostate cancer appear to vary widely basedon initial treatment and these are likely to increase with the introduction of more expensive services andpharmaceuticals. There is a pressing need for better prognostic tools to distinguish between indolent andaggressive prostate tumors to reduce potential over treatment and help ease the burden of prostate cancer. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Wiley-Blackwell Publishing | |
dc.relation.ispartofpagefrom | 152 | |
dc.relation.ispartofpageto | 159 | |
dc.relation.ispartofissue | 3 | |
dc.relation.ispartofjournal | Asia-Pacific Journal of Clinical Oncology | |
dc.relation.ispartofvolume | 13 | |
dc.subject.fieldofresearch | Oncology and carcinogenesis | |
dc.subject.fieldofresearch | Oncology and carcinogenesis not elsewhere classified | |
dc.subject.fieldofresearchcode | 3211 | |
dc.subject.fieldofresearchcode | 321199 | |
dc.title | What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year? | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.faculty | Griffith Health, School of Medicine | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Chambers, Suzanne K. | |